Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Genoptix, Inc. (“Genoptix” or the “Company”) (Nasdaq: GXDX) relating to the proposed acquisition by Novartis AG (NYSE: NVS) in a transaction valued at approximately $470 million.

Under the terms of the offer, Genoptix shareholders would receive cash of $25.00 for each share of Genoptix stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law. The transaction appears to be unfair, in part, given the 52 week high trading high for the Company’s stock was $38.79 a share. Additionally, at least one analyst has set a target price of $28.00 for Genoptix stock.

If you own shares of Genoptix and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, or by calling toll free 877-LEGAL-90.

Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Genoptix, Inc. (MM).
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Genoptix, Inc. (MM).